Korean J Physiol Pharmacol.  2012 Oct;16(5):339-342. 10.4196/kjpp.2012.16.5.339.

Genetic Polymorphisms of Cytochrome P450 2C19 in Functional Dyspeptic Patients Treated with Cimetidine

• Kim M
• Kong E

• KMID: 1493967
• DOI: http://doi.org/10.4196/kjpp.2012.16.5.339

Abstract

Inter-individual pharmacokinetic variation of H2-receptor antagonist is related to genetic polymorphism of CYP2C19. We investigated the frequency of CYP2C19 genetic polymorphism and the treatment duration of cimetidine by CYP2C19 genotypes in functional dyspeptic patients without definite causes who were treated with cimetidine in Korea. One hundred subjects with functional dyspepsia participated in this study from March 1, 2010 to June 30, 2011. They were tested by upper gastrointestinal endoscopy and treated for their dyspepsia with cimetidine. The single nucleotide polymorphisms (SNPs) of CYP2C19 were genotyped using the Seeplex CYP2C19 ACE Genotyping system. There were no significant differences in the demographic, clinical, or laboratory findings among the CYP2C19 subgroups which are wild type homozygote (W/W), heterozygote (W/V), and variant homozygote (V/V). The frequencies of CYP2C19 subgroups were 33 (33%) in W/W, 49 (49%) in W/V, and 18 (18%) in V/V, respectively. The mean duration of cimetidine treatment (in weeks) was the shortest in the V/V among the CYP2C19 genotypes (W/W: 5.1+/-1.5, W/V: 4.0+/-1.7, V/V: 2.1+/-0.7; p<0.001). This study can also act as a basis for further investigation to identify the underlying genetic, epigenetic, or environmental factors in CYP2C19 enzyme activity.

Keyword

Cimetidine; CYP2C19; Dyspepsia

MeSH Terms

Cimetidine
Cytochrome P-450 Enzyme System
Cytochromes
Dyspepsia
Endoscopy, Gastrointestinal
Epigenomics
Genotype
Heterozygote
Homozygote
Humans
Korea
Polymorphism, Genetic
Polymorphism, Single Nucleotide
Cimetidine
Cytochrome P-450 Enzyme System
Cytochromes

Figure

• 

  Fig. 1 Mean treatment duration (weeks) by CYP2C19 genotypes in functional dyspeptic patients who were treated with cimetidine in Korea. It showed significant differences among the different CYP2C19 subgroups. It was the shortest in the V/V among the CYP2C19 genotypes (wild type homozygote: 5.1±1.5, heterozygote: 4.0±1.7, variant homozygote: 2.1±0.7; p<0.001).

Reference

1. Andersen PM. Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. 1:Suppl 1. S31–S42.

2. Lee AY, Lee KH, Ko DS, Chey WY. Constitutive expression and changes of cytochrome P450 isozymes mRNAs by vehicles (petrolatum, DMSO, ethanol) in rat skin using semi-quantitative RT-PCR. Korean J Physiol Pharmacol. 2001. 5:407–412.

3. Badyal DK, Dadhich AR. Cytochrome p450 and drug interactions. Indian J Pharmacol. 2001. 33:248–259.

4. Wijnen PA, Op den Buijsch RA, Drent M, Kuijpers PM, Neef C, Bast A, Bekers O, Koek GH. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007. 26:Suppl 2. 211–219.

5. Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet. 1995. 29:Suppl 1. 45–52.

6. Chun JY, Kim KJ, Hwang IT, Kim YJ, Lee DH, Lee IK, Kim JK. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. Nucleic Acids Res. 2007. 35:e40.

7. Sheu BS, Cheng HC, Yeh YC, Chang WL. CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D. J Gastroenterol Hepatol. 2012. 27:104–109.

8. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001. 52:349–355.

9. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998. 20:243–247.

10. Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006. 80:33–40.

11. Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19^*2, CYP2C19^*3, and CYP2C19^*17 alleles. J Clin Pharm Ther. 2010. 35:697–703.

12. Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect. 2007. 135:171–176.